HYTN Clears PIC/S GMP Audit, Primed for Global Expansion
VANCOUVER, British Columbia, March 04, 2024 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0) (the “Company” or “HYTN”), a company at the forefront of developing, formulating, and manufacturing products with psychoactive and psychotropic compounds, including those from cannabis and psilocybin, proudly announces the successful completion of a Good Manufacturing Practices (“GMP”) audit by Australia’s Therapeutic Goods Administration (“TGA”) at their Kelowna facility. The positive outcome of the audit has set the stage for the subsequent issuance of formal GMP certification allowing the company to access international medical markets.
Related news for (HYTNF)
- HYTN Completes Acquisition of Prism Scientific Labs, Enhancing Psychedelic Compound Manufacturing Capabilities
- HYTN Awarded Drug Establishment License from Health Canada, Expanding GMP Capabilities
- HYTN Welcomes U.S. Recommendation to Reclassify Cannabis, Foresees Growth
- HYTN Innovates GMP Stability Programs, Sets Industry Benchmark
- HYTN Welcomes Health Canada for Audit to Enhance GMP Capabilities